
CLAIMS

1. A compound represented by the formula (I):



(I)

wherein

~~R^1 is~~

~~(1) a C_{1-6} alkyl group,~~

~~(2) a mono- or di-C_{1-6} alkylamino group, or~~

~~(3) a C_{3-6} cycloalkyl group;~~

~~R^2 is~~

~~(1) a hydrogen atom,~~

~~(2) a fluorine atom, or~~

~~(3) a C_{1-6} alkyl group;~~

~~R^3 is~~

~~(1) a C_{1-6} alkyl-carbonyl group optionally substituted by 1 to 3 substituents selected from~~

~~(a) a halogen atom,~~

~~(b) a hydroxy group, and~~

~~(c) a cyano group,~~

~~(2) a C_{1-6} alkoxy-carbonyl group,~~

~~(3) a C_{3-10} cycloalkyl-carbonyl group (the C_{3-10} cycloalkyl moiety of the C_{3-10} cycloalkyl-carbonyl group is optionally bridged) optionally substituted by 1 to 3 substituents selected from~~

~~(a) a halogen atom,~~

~~(b) a hydroxy group,~~

~~(c) a cyano group, and~~

~~(d) a C_{1-6} alkyl group,~~

(4) a 3- to 14-membered non-aromatic heterocyclylcarbonyl group optionally substituted by 1 to 3 substituents selected from

(a) a halogen atom,

(b) a hydroxy group, and

(c) a C_{1-6} alkyl group,

(5) a mono- or di-C_{1-6} alkyl-carbamoyl group,

(6) a N-C_{1-6} alkyl-N-C_{1-6} alkoxy-carbamoyl group, or

(7) a N-C_{1-6} alkyl-N',N'-di-C_{1-6} alkylhydrazine-carbonyl group; and

Ring A is

(1) a benzene ring

further substituted by one substituent selected from

(a) a C_{6-14} aryl group optionally substituted by 1 to 3 substituents selected from

(i) a halogen atom,

(ii) an optionally halogenated C_{1-6} alkyl group, and

(iii) an optionally halogenated C_{1-6} alkoxy group, and

(b) a 5- to 14-membered aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from

(i) a C_{1-6} alkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a hydroxy group,

(ii) a C_{1-6} alkoxy group,

(iii) a halogen atom, and

(iv) a C_{1-6} alkoxy-carbonyl group, and

optionally further substituted by 1 to 3 halogen atoms, or

(2) a 5- or 6-membered aromatic heterocycle further substituted by one C_{6-14} aryl group optionally substituted by 1 to 3 halogen atoms,

or a salt thereof.

~~2. The compound or salt according to claim 1, wherein~~

R^1 is

(1) a C_{1-6} alkyl group,

(2) a mono- or di-C_{1-6} alkylamino group, or

(3) a C_{3-6} cycloalkyl group;

R^2 is

(1) a hydrogen atom, or

(2) a fluorine atom;

R^3 is

(1) a C_{1-6} alkyl-carbonyl group optionally substituted by 1 to 3 hydroxy groups,

(2) a C_{3-10} cycloalkyl-carbonyl group (the C_{3-10} cycloalkyl moiety of the C_{3-10} cycloalkyl-carbonyl group is optionally bridged) optionally substituted by 1 to 3 substituents selected from

(a) a halogen atom, and

(b) a hydroxy group,

(3) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group, or

(4) a mono- or di-C_{1-6} alkyl-carbamoyl group; and

Ring A is a benzene ring

further substituted by one C_{6-14} aryl group optionally substituted by 1 to 3 substituents selected from

(i) a halogen atom, and

(ii) an optionally halogenated C_{1-6} alkyl group, and

optionally further substituted by 1 to 3 halogen atoms, or a salt thereof.

~~3~~2. The compound or salt according to claim 1, wherein

R^1 is

(1) a C_{1-6} alkyl group, or

(2) a mono- or di-C_{1-6} alkylamino group;

R^2 is

(1) a hydrogen atom, or

(2) a fluorine atom;

R^3 is

(1) a C_{1-6} alkyl-carbonyl group optionally substituted by 1 to 3 hydroxy groups,

(2) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group, or

(3) a mono- or di-C_{1-6} alkyl-carbamoyl group; and

Ring A is a benzene ring

further substituted by one C_{6-14} aryl group optionally substituted by 1 to 3 substituents selected from

(i) a halogen atom, and

(ii) a C_{1-6} alkyl group, and

optionally further substituted by 1 to 3 halogen atoms.

~~4~~3. N'-{(2S,3R,4S)-1-(azetidine-1-carbonyl)-4-fluoro-2-[(2-fluoro-3'-methyl[1,1'-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}-N,N-dimethylsulfuric diamide or a salt thereof.

~~5~~4. N-[(2S,3R)-2-[(2,3'-difluoro[1,1'-biphenyl]-3-yl)methyl]-4,4-difluoro-1-(2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide or a salt thereof.

~~6~~5. N-{(2S,3R)-4,4-difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3',5'-trifluoro[1,1'-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide or a salt thereof.

~~7~~6. A medicament comprising the compound or salt according to claim 1.

~~8~~7. The medicament according to claim ~~7~~6, which is an orexin type 2 receptor agonist.

~~9~~8. The medicament according to claim ~~7~~6, which is an agent for the prophylaxis or treatment of narcolepsy.

~~10~~9. The compound or salt according to claim 1 for use in the

prophylaxis or treatment of narcolepsy.

~~11~~10. The compound or salt according to claim 1 for use in activating an orexin type 2 receptor in a mammal, wherein an effective amount of the compound or salt according to claim 1 is to be administered to the mammal.

~~12~~11. Use of the compound or salt according to claim 1 in the manufacture of a medicament for the prophylaxis or treatment of narcolepsy.

~~13~~12. The compound or salt according to claim 1 for use in medicine.